

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michela Gallagher
Application No. : 10/722,357 Confirmation No. 4705
Filed : November 24, 2003
For : TARGET FOR THERAPY OF COGNITIVE
IMPAIRMENT
Group Art Unit : 1611
Examiner : Kyle A. Purdy

New York, New York 10036
January 7, 2010

Mail Stop RCE
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make the following documents of record in the above-identified patent application:*

Non-Patent Literature Documents

Allain *et al.*, "Treatment of the Mild Cognitive Impairment (MCI)," *Human Psychopharmacology: Clinical and Experimental*, 22: 189-197 (2007).

* A completed Form PTO/SB/08A/B listing these documents is attached hereto.

Aisop *et al.*, "Hippocampal Hyperperfusion in Alzheimer's Disease," *NeuroImage*, 42: 1267-1274 (2008)

Dickerson *et al.*, "Increased Hippocampal Activation in Mild Cognitive Impairment Compared to Normal Aging and AD," *Neurology*, 65: 404-411 (2005)

Fernandez *et al.*, "Mild Cognitive Impairment in Parkinson's Disease: The Challenge and the Promise," *Neuropsychiatric Disease and Treatment*, 1: 37-50 (2005)

Grundman *et al.*, "Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials," *Archives of Neurology*, 61:59-66 (2004)

Herrmann *et al.*, "Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease," *The Canadian Journal of Psychiatry*, 52: 630-646 (2007)

Petersen *et al.*, "Mild Cognitive Impairment," *Archives of Neurology*, 56:303-308 (1999)

Petersen *et al.*, "Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment," *The New England Journal of Medicine*, 352: 2379-2388 (2005)

Porsteinsson *et al.*, "Placebo-Controlled Study of Divalproex Sodium for Agitation in Dementia," *American Journal of Geriatric Psychiatry*, 9: 58-66 (2001)

Rapp *et al.*, "Preserved Neuron Number in the Hippocampus of Aged Rats with Spatial Learning Deficits," *Proceedings of the National Academy of Sciences USA*, 93: 9926-9930 (1996)

Roberts *et al.*, "The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics," *Neuroepidemiology*, 30: 58-69 (2008)

Sival *et al.*, "Sodium Valproate in the Treatment of Aggressive Behavior in Patients with Dementia--A Randomized Placebo Controlled Clinical Trial," *International Journal of Geriatric Psychiatry*, 17: 579-85 (2002)

Tariot *et al.*, "Alzheimer's Disease Cooperative Study: Chronic Valproate Therapy To Attenuate The Clinical Progression Of Alzheimer's Disease," 2009 International Conference on Alzheimer's Disease

Tariot *et al.*, "Divalproex Sodium in Nursing Home Residents with Possible or Probable Alzheimer Disease Complicated by Agitation," *American Journal of Geriatric Psychiatry*, 13: 942-49 (2005)

Tariot *et al.*, "Safety and Tolerability of Divalproex Sodium in the Treatment of Signs and Symptoms of Mania in Elderly Patients with Dementia: Results

of a Double-Blind, Placebo-Controlled Trial," *Current Therapeutic Research*, 62: 51-67 (2001)

Thal *et al.*, "Randomized, Double-blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment," *Neuropsychopharmacology*, 30: 1204-1215 (2005)

Wilson *et al.*, "Neurocognitive Aging: Prior Memories Hinder New Hippocampal Encoding," *Trends Neuroscience*, 29: 662-670 (2006)


Copies of the aforementioned documents, which are listed on the accompanying Form PTO/SB/08A/B, are enclosed herewith.

Applicants respectfully request that the above documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO/SB/08A/B, as considered and duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

This Statement is being submitted concurrently with a request for continued examination under 37 C.F.R. § 1.114. In accordance with 37 C.F.R. § 1.97(b)(4), applicants believe that submission of this Statement requires no fee. If, however, any additional fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. JHUC-008-101.

Consideration of the foregoing in relation to this patent application is respectfully requested.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants

ROPES & GRAY LLP
Customer No. 1473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (212) 596-9090